IBEX 35
11.114,30 +82,00 (+0,74%) Euro Stoxx 50
4.943,17 +35,87 (+0,73%) Dólar/Euro
1,0732 +0,0034 (+0,32%) Petróleo Brent
85,47 +0,23 (+0,27%) Oro
2.338,60 +7,40 (+0,32%) Bitcoin EUR
57.211,52 -2.706,27 (-4,52%)
Tanvex BioPharma, Inc. (6541.TW)
Tanvex BioPharma, Inc.
802 West Bay Road
Grand Pavilion Hibiscus Way PO Box 31119
George Town KY1-1205
Cayman Islands
https://www.tanvex.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 167
Descripción
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Gobierno corporativo
El ISS Governance QualityScore de Tanvex BioPharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
